This inhibitor perturbs the KRas4B-PDE6δ interaction, reduces proliferation and ERK1 phosphorylation in KRas4B-transformed pancreatic cancer cell lines, as well as tumor growth in xenografts of human pancreatic carcinoma cells [6]. This evidence concerns the gene PDE6D and familial pancreatic carcinoma.